Search results for "Samsung Bio"

Red Patches on the Skin: Diagnostic Model Distinguishes Bowen’s Disease From Precancerous Lesions With 95% Accuracy

Red Patches on the Skin: Diagnostic Model Distinguishes Bowen’s Disease From Precancerous Lesions With 95% Accuracy

If a red patch appears on the skin and begins to scale, could it be skin cancer? Distinguishing early-stage skin cancer from precancerous lesions can...
Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels

Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels

Pediatric and adolescent Crohn’s disease patients who switch to infliximab after losing responsiveness to adalimumab display lower drug...
Samsung Biologics Slashes Biopharma Development Timeline to 9.5 Months at BioProcess International 2026

Samsung Biologics Slashes Biopharma Development Timeline to 9.5 Months at BioProcess International 2026

Samsung Biologics has unveiled a process innovation case study demonstrating a reduction in biopharmaceutical...
Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Samsung Biologics is proceeding with a 3 trillion won ($2.25 billion) rights offering, directing approximately 90% of...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms

Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms

Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

With wage and collective bargaining talks between Samsung Biologics and its union still unresolved, analysts expect...
Samsung Bioepis Expands Global Open Innovation via Partnership With Chinese Biotech Hub

Samsung Bioepis Expands Global Open Innovation via Partnership With Chinese Biotech Hub

Samsung Bioepis announced on the 29th that it has signed a memorandum of understanding with Atlalt Innovation Center, a...